Summit Trail Advisors LLC boosted its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 135.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,227 shares of the medical research company's stock after purchasing an additional 2,433 shares during the period. Summit Trail Advisors LLC's holdings in Agilent Technologies were worth $569,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory purchased a new position in Agilent Technologies in the third quarter valued at about $28,000. CKW Financial Group increased its holdings in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. increased its holdings in Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after buying an additional 116 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Agilent Technologies in the third quarter valued at about $31,000. Finally, Fortitude Family Office LLC increased its holdings in Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock valued at $35,000 after buying an additional 95 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on A. JPMorgan Chase & Co. dropped their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research note on Tuesday, November 26th. Sanford C. Bernstein dropped their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating for the company in a research note on Tuesday, November 26th. Wells Fargo & Company dropped their price objective on shares of Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating for the company in a research note on Monday, December 9th. StockNews.com raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Finally, Bank of America dropped their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $144.38.
Check Out Our Latest Stock Analysis on A
Insider Activity at Agilent Technologies
In related news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company's stock, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Agilent Technologies Trading Down 1.4 %
Shares of A traded down $1.88 during mid-day trading on Friday, reaching $134.57. The company had a trading volume of 1,358,730 shares, compared to its average volume of 1,732,627. The stock has a market cap of $38.39 billion, a price-to-earnings ratio of 30.45, a price-to-earnings-growth ratio of 4.00 and a beta of 1.07. The firm has a fifty day simple moving average of $141.53 and a 200-day simple moving average of $139.41. Agilent Technologies, Inc. has a fifty-two week low of $124.16 and a fifty-two week high of $155.35. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57.
Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the business earned $1.38 EPS. On average, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.56 EPS for the current fiscal year.
Agilent Technologies Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st were issued a dividend of $0.248 per share. This is a positive change from Agilent Technologies's previous quarterly dividend of $0.24. The ex-dividend date was Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.74%. Agilent Technologies's payout ratio is presently 22.40%.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Recommended Stories
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
